Your AI-Trained Oncology Knowledge Connection!
The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.
Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.
Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.
The FDA has granted breakthrough therapy designation to CLN-081 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy.
The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma.
Sara Tolaney, MD, MPH, discusses the data with the oral selective estrogen receptor degrader, elacestrant, and the androgen receptor agonist, enobosarm, in estrogen receptor–positive, HER2-negative breast cancer.
Maurie Markman, MD, shares how evidence strongly supports that approaches to cancer prevention have little chance of success unless those being targeted are willing to listen to, and ultimately trust, the recommendations being made by members of the scientific community.
With an influx of new trials examining the use of anti-EGFR treatments in patients with advanced colorectal cancer, attention must be paid to finding the optimal window in which to give these therapies to maximize benefit.
The FDA has granted a fast track designation to a combination comprised of the immunogene therapy quaratusugene ozeplasmia and pembrolizumab for use in select patients with late-stage non–small cell lung cancer.
Marina Kremyanskaya, MD, PhD, discusses potential new combinations for treating patients with myelofibrosis and other MPNs, with a backbone of ruxolitinib.
A new drug application seeking the approval of valemetostat tosylate for use in the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma has been submitted to the Japanese Ministry of Health, Labour, and Welfare.
MUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients.
The European Medicines Agency has validated the Type II Variation application for fam-trastuzumab deruxtecan-nxki as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 1 or more anti–HER2-based regimens.
The Japanese Ministry of Health, Labour, and Welfare has approved the combination of pembrolizumab plus lenvatinib for use in patients with unresectable, advanced, or recurrent endometrial carcinoma that has progressed on chemotherapy.
Bintrafusp Alfa, a novel fusion protein designed to target the transforming growth factor beta pathway, racked up 3 clinical trial disappointments in less than a year, leaving the future of its development in question.
Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate enobosarm in estrogen receptor–positive, androgen receptor–positive metastatic breast cancer, prior data observed with the agent, and the unmet needs positive results of the ARTEST trial could potentially fulfill.
Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy with immune checkpoint inhibitors in bladder cancer, while several other early-phase studies are testing novel agents in solid tumors.
Robert Ramirez, DO, FACP, details his path to clinical thoracic oncology after originally planning on entering the academic field early in his career.
Despite advances in treatments for T-cell acute lymphoblastic leukemia, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of the disease, as well as the need to discover new targeted therapeutic approaches and treatment resistance
Oleg Bess, MD, explains why data quality is essential to improving the United States health care system.
Naresh Bumma, MD, discusses the focus of each presentation on frontline therapy, early and late relapse, and CAR T-cell therapy in multiple myeloma.
Jyoti D. Patel, MD, discusses biomarker testing, interpreting molecular result reports, and the growing armamentarium for patients with oncogene-driven lung cancer.
Nathan Bahary, MD, PhD, a medical oncologist, was most recently the medical director of the Pancreatic Cancer Program, co-director of the UPMC Pancreatic Cancer Center of Excellence, and co-director of the UPMC Phase II program.
The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.
The armamentarium of multiple myeloma has expanded with the introduction of combination regimens in the up-front setting and novel targeted agents, including CAR T-cell therapy, in the relapsed/refractory setting.
A biologics license application seeking the approval of teclistamab for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.
The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.
American Oncology Network, LLC is pleased to announce that eight research studies co-authored by AON physicians were presented at the American Society of Hematology Annual Meeting & Exposition, held December 11-14, 2021.
Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.
Data from key clinical trials evaluating expanded combination strategies and novel therapies have transformed the treatment paradigms of newly diagnosed, relapsed/refractory, and heavily pretreated multiple myeloma, but it remains important to contextualize the data appropriately without cross-trial comparisons.
